Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on World Healthcare Report.
Press releases published on May 6, 2025
Microbiotica unveils multiple mechanisms by which MB310, in clinical development for the treatment of ulcerative colitis, protects the intestinal barrier
GlobeNewswire
·
May 6, 2025
CAMBRIDGE, United Kingdom, May 06, 2025 (GLOBE NEWSWIRE) -- Microbiotica, a clinical-stage biopharma Company developing a pipeline of oral precision microbiome medicines called live biotherapeutic products (LBPs), has presented new data on the mechanism of …
Essential Pharma strengthens management team with appointment of Duncan Ferguson as Vice President, Commercial
GlobeNewswire
·
May 6, 2025
Egham, UK – 6th May 2025 – Essential Pharma (“Essential” or “the Company”), a global pharmaceutical company developing and delivering medicines for patients in niche populations, today announces the appointment of Duncan Ferguson as Vice President, …
Priothera Appoints Dr. Jens Hasskarl as Chief Medical Officer to Drive Late-Stage Clinical Development of Mocravimod, a S1P Receptor Modulator for Acute Myeloid Leukemia (AML)
GlobeNewswire
·
May 6, 2025
Dr. Hasskarl to lead global Phase 3 MO-TRANS study evaluating mocravimod as an adjunctive treatment to allo-HCT in AML Saint-Louis, France and Dublin, Ireland – 6th May 2025– Priothera Ltd., a late-stage biopharma company pioneering the development of …
New Analysis Published in Nature Medicine Demonstrates Advantages of Nationwide Coronary CTA Strategy with Heartflow FFRCT in Over 90,000 Patients with Coronary Artery Disease
GlobeNewswire
·
May 6, 2025
MOUNTAIN VIEW, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Heartflow, Inc., the leader in AI technology for coronary artery disease (CAD), today announced two-year data from FISH…
Angelini Ventures Co-Leads $45 Million Series B Financing of Nuevocor to Advance Transformative Treatment for Genetic Dilated Cardiomyopathy
GlobeNewswire
·
May 6, 2025
Angelini Ventures marks its first investment in the cardiovascular and gene therapy space – and first in Asia, further diversifying its strong and growing portfolio Rome, Italy - 6 May 2025 – Angelini Ventures, the corporate venture firm of Angelini …
TestoPrime Review and Results: A 30 Day Test By WhatBest Reveals Results Of Using TestoPrime For 1 Month.
GlobeNewswire
·
May 6, 2025
New York, May 06, 2025 (GLOBE NEWSWIRE) -- WhatBest, a leading product review and comparison platform, has published a detailed 30-day user review of TestoPrime, a natural testosterone support supplement gaining traction among men looking to boost energy, …
Ipsen appoints Laura Réveillon as EVP, Strategy & Transformation
GlobeNewswire
·
May 6, 2025
PARIS, FRANCE, 06 May 2025 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty care-driven biopharmaceutical company, announced today the appointment of Laura Réveillon, PhD as EVP, Strategy …
Ipsen nomme Laura Réveillon au poste de Vice-Présidente Exécutive, Stratégie et Transformation
GlobeNewswire
·
May 6, 2025
PARIS, FRANCE, 6 mai 2025 - Ipsen (Euronext : IPN ; ADR : IPSEY), groupe biopharmaceutique mondial de spécialité, a annoncé aujourd'hui la nomination de Laura Réveillon, PhD, au poste de Vice-Présidente Exécutive, Stratégie et Transformation, à compter …
argenx to Present at BofA Securities 2025 Health Care Conference
GlobeNewswire
·
May 6, 2025
May 6, 2025 Amsterdam, the Netherlands – argenx (Euronext …
Novaremed Announces Completion of Enrollment in NIH-sponsored Phase 2b Study with Non-opioid NRD.E1 for the Treatment of Chronic Pain Associated with Diabetic Peripheral Neuropathy
GlobeNewswire
·
May 6, 2025
Last patient first visit (LPFV) marks completion of enrollment of 127 adult and elderly patients in the randomized, placebo-controlled trial -- topline data is expected in Q4 2025 This study builds on Phase 2a proof-of-concept results, which showed a …
Philips delivers on Q1 results, with ongoing order intake growth
GlobeNewswire
·
May 6, 2025
May 6, 2025 Q1 2025 Group performance Group sales EUR 4.1 billion, reflecting a 2% decline in comparable sales growth mainly due to China; slightly ahead of company outlook due to Personal Health growth and royalty phasing Comparable order intake increased …
Correction From Source: Firefly Neuroscience Achieves Multi-Fold Database, IP Portfolio, and Commercial Footprint Expansion Through Acquisition of Evoke Neuroscience, Inc.
GlobeNewswire
·
May 6, 2025
A correction from source is being issued with respect to the press release titled, Firefly Neuroscience Achieves Multi-Fold Database, IP Portfolio, and Commercial Footprint Expansion Through Acquisition of Evoke Neuroscience, Inc., released on May 5, 2025 …